Plasma nevirapine levels and 24-week efficacy in HIV-infected patients receiving nevirapine-based highly active antiretroviral therapy with or without rifampicin

Clinical Infectious Diseases

Volumn 43, Issue 2, 2006, Pages 253-255

  Manosuthi, Weerawat ^a,d   Sungkanuparph, Somnuek ^b   Thakkinstian, Ammarin ^b   Rattanasiri, Sasivimol ^b   Chaovavanich, Achara ^a   Prasithsirikul, Wisit ^a   Likanonsakul, Sirirat ^a   Ruxrungtham, Kiat ^c  

^a MINISTRY OF PUBLIC HEALTH   (Thailand)

^b MAHIDOL UNIVERSITY   (Thailand)

^c THAI RED CROSS AIDS RESEARCH CENTRE   (Thailand)

^d Bamrasnaradura Infectious Diseases Institute   (Thailand)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ANTIRETROVIRUS AGENT; LAMIVUDINE; NEVIRAPINE; RIFAMPICIN; STAVUDINE; TUBERCULOSTATIC AGENT;

ABNORMALLY HIGH SUBSTRATE CONCENTRATION IN BLOOD; ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; CD4 LYMPHOCYTE COUNT; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG SAFETY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; RASH; TOXIC HEPATITIS; TREATMENT OUTCOME; TUBERCULOSIS; VIRUS LOAD;

ADULT; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; ANTITUBERCULAR AGENTS; DRUG INTERACTIONS; FEMALE; HIV INFECTIONS; HUMANS; MALE; NEVIRAPINE; PROSPECTIVE STUDIES; RIFAMPIN; TREATMENT OUTCOME; TUBERCULOSIS;

EID: 33745700384     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/505210     Document Type: Article

References (12)

1. van Leth F, Phanuphak P, Ruxrungtham K, et al. Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open-label trial, the 2NN Study. Lancet 2004; 363:1253-63.
2. Manosuthi W, Sungkanuparph S, Vibhagool A, Rattanasiri S, Thakkinstian A. Nevirapine- versus efavirenz-based highly active antiretroviral therapy regimens in antiretroviral-naive patients with advanced HIV infection. HIV Med 2004; 5:105-9.
3. Fox W, Ellard GA, Mitchison DA. Studies on the treatment of tuberculosis undertaken by the British Medical Research Council tuberculosis units, 1946-1986, with relevant subsequent publications. Int J Tuberc Lung Dis 1999; 3:5231-79.
4. Finch CK, Chrisman CR, Baciewicz AM, Self TH. Rifampin and rifabutin drug interactions: an update. Arch Intern Med 2002; 162:985-92.
5. Ribera E, Pou L, Lopez RM, et al. Pharmacokinetic interaction between nevirapine and rifampicin in HIV-infected patients with tuberculosis. J Acquir Immune Defic Syndr 2001; 28:450-3.
6. Ramachandran G, Hemanth K, Rajasekaran S, et al. Increasing nevirapine dose can overcome reduced bioavailability due to rifampicin co-administration (abstract WePe3.3C02). In: Program and abstracts of the 3rd IAS Conference on HIV Pathogenesis and Treatment (Rio de Janeiro, Brazil). 2005.
7. Oliva J, Moreno S, Sanz J, et al. Co-administration of rifampin and nevirapine in HIV-infected patients with tuberculosis. AIDS 2003; 17:637-8.
8. Veldkamp AI, Weverling GJ, Lange JM, et al. High exposure to nevirapine in plasma is associated with an improved virological response in HIV-1-infected individuals. AIDS 2001; 15:1089-95.
9. Havlir D, Cheeseman SH, McLaughlin M, et al. High-dose nevirapine: safety, pharmacokinetics, and antiviral effect in patients with human immunodeficiency virus infection. J Infect Dis 1995; 171:537-45.
10. Manosuthi W, Chumpathat N, Chaovavanich A, Sungkanuparph S. Safety and tolerability of nevirapine-based antiretroviral therapy in HIV-infected patients receiving fluconazole for cryptococcal prophylaxis: a case-control study. BMC Infect Dis 2005; 5:67.
11. World Health Organization (WHO). Scaling up antiretroviral therapy in resource-limited settings: treatment guidelines for a public health approach. Geneva: Joint United Nations Programme on HIV/AIDS and WHO, 2003.
12. del Rio C. Updated guidelines for the use of rifamycins in HIV/TB-coinfected patients. AIDS Clin Care 2004; 16:85.